LENZ Misses Q3 Estimates as Revenue Falls 72.9%
LENZ is trading near its 52-week low of $3.06 (2.0% below the low).
Summary
LENZ posted a Q3 adjusted loss of 99 cents a share, worse than the 91-cent consensus, on revenue of $3.38 million that fell 72.9% year over year and came in below the $4.20 million analysts expected. The net loss was $30.97 million. This follows the Oct 28 release that flagged VIZZ sales of $2.6 million, up about 50% sequentially, and a headcount-cutting reorganization — the top line still badly trails the year-ago comparison even as the launch product grows. With the stock at $3.00 near its 52-week low of $3.06 and down 79.9% this year, the miss reinforces how far the DTC-funded launch is from covering costs. Cash burn is the number that matters now; the last 10-Q showed $220 million in reserves.
At the time of this announcement, LENZ was trading at $3.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $100.9M. The 52-week trading range was $3.06 to $32.13. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.